Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
After customs duty cuts on 17 cancer drugs, India’s price regulator ordered MRPs revised to pass on benefits, but activists say tax relief alone won’t make costly patented therapies affordable.
In a follow-up to the customs duty relief on essential medicines, the National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers and marketing companies of the ...
ABP News on MSN
ABP Exclusive | Budget 2026 Cuts Duty On 17 Drugs: Will Cancer Patients Finally See Real Relief Or Is Cost Still The Bigger Battle?
Earlier this month, Finance Minister Nirmala Sitharaman presented the Budget 2026-27, which mentioned the prices of 17 drugs coming down owing to the exemption of duty taxes. By abolishing basic ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey. Real-world outcomes by race in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
Roche/AbbVie’s cancer drug venetoclax, which is set to become standard of care in chronic lympocytic leukaemia, could further improve prognosis earlier in the disease according to a UK expert.
NPPA asks cos to revise prices of 17 drugs following BCD exemption: Gireesh Babu, New Delhi Thursday, February 12, 2026, 08:00 Hrs [IST] The National Pharmaceutical Pricing Author ...
Roche and AbbVie’s Venclexta approved in CLL Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with ...
2d
Mendus AB (STU:1YG0) Q4 2025 Earnings Call Highlights: Promising Trials and Financial Maneuvers ...
Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results